氮杂环庚烷-2-酮肟 | 19214-08-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 中文名称: 氮杂环庚烷-2-酮肟
• 英文名称: perhydro-2-azepinone oxime
• 英文别名: azepan-2-one oxime；hexahydro-azepin-2-one oxime；Hexahydro-azepin-2-on-oxim；2-hydroximinohomopiperidine；α-Hydroxyiminocaprolactam；2-Oximino-perhydro-azepin；N-(3,4,5,6-tetrahydro-2H-azepin-7-yl)hydroxylamine
• CAS: 19214-08-5
• 化学式: C₆H₁₂N₂O
• mdl: MFCD00053062
• 分子量: 128.174
• InChiKey: PPOHPUOKXMNCCI-UHFFFAOYSA-N

物化性质

• 熔点：
  169-170 °C
• 沸点：
  247.4±23.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  44.6
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2933990090

SDS

Name:	Azepan-2-one oxime 97% Material Safety Data Sheet
Synonym:	Hexahydro-2H-azepin-2-one oxim
CAS:	19214-08-5

Section 1 - Chemical Product MSDS Name:Azepan-2-one oxime 97% Material Safety Data Sheet
Synonym:Hexahydro-2H-azepin-2-one oxim

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
19214-08-5	Azepan-2-one oxime		unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 19214-08-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 168 - 170 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H12N2O
Molecular Weight: 128

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 19214-08-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Azepan-2-one oxime - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 19214-08-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 19214-08-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 19214-08-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  氮杂环庚烷-2-酮肟 在 sodium hydroxide 、 甲基三辛基氯化铵 作用下， 以 吡啶 、 二氯甲烷 为溶剂， 反应 2.75h， 生成 (E)-9-Phenyl-1,7,9-triaza-bicyclo[6.2.0]dec-7-en-10-one
  参考文献：
  名称：

  Synthesis and reactions of cyclic carbodiimides

  摘要：

  DOI：

  10.1021/jo00158a022
• 作为产物：
  描述：

  1-氮杂-2-甲氧基-1-环庚烯 在 盐酸羟胺 、 碳酸氢钠 作用下， 以 甲醇 为溶剂， 生成 氮杂环庚烷-2-酮肟
  参考文献：
  名称：

  Synthesis and reactions of cyclic carbodiimides

  摘要：

  DOI：

  10.1021/jo00158a022

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20100069348A1

  公开（公告）日：2010-03-18

  Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A 1 , A 5 , R x , X 4 , and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文揭示了公式（I）中的大麻素受体配体，其中A1、A5、Rx、X4和z如规范中定义。还公开了包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病和疾病的方法。
• [EN] TETRAHYDRO-4H-PYRIDO[1,2-A]PYRIMIDINES AND RELATED COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS<br/>[FR] TETRAHYDRO-4H-PYRIDO[1,2-A]PYRIMIDINES ET COMPOSES CONNEXES CONVENANT COMME INHIBITEURS DE L'INTEGRASE DU VIH
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2004058756A1

  公开（公告）日：2004-07-15

  Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (A): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4, R12, R14, R16, R30, R32, R34 and R36 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  Tetrahydro-4H-pyrido[1,2-a]pyrimidines及其相关化合物的化学式（A）如下：被描述为HIV整合酶的抑制剂和HIV复制的抑制剂，其中n是一个等于零、1、2或3的整数，而R1、R3、R4、R12、R14、R16、R30、R32、R34和R36在此处被定义。这些化合物对预防和治疗HIV感染以及预防、延缓艾滋病发作和治疗艾滋病具有用处。这些化合物可作为化合物本身或作为药学上可接受的盐的形式用于对抗HIV感染和艾滋病。这些化合物及其盐可作为药物组合物的成分，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。
• Heterobicyclic and tricyclic nitric oxide synthase inhibitors
  申请人：——

  公开号：US20010044539A1

  公开（公告）日：2001-11-22

  The current invention discloses useful bicyclic and tricyclic amidino derivative compounds, pharmaceutical compositions containing these novel compounds, and to their use as nitric oxide synthase inhibitors.

  当前的发明揭示了有用的双环和三环氨基甲酰衍生物化合物，含有这些新化合物的药物组合物，以及它们作为一氧化氮合酶抑制剂的用途。
• [EN] TETRAHYDRO-4H-PYRIDO[1,2-A]PYRIMIDINES AND RELATED COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS<br/>[FR] TETRAHYDRO-4H-PYRIDO[1,2-A]PYRIMIDINES ET COMPOSES ASSOCIES UTILISES EN TANT QU'INHIBITEURS DE L'INTEGRASE DU VIH
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2004058757A1

  公开（公告）日：2004-07-15

  Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (I): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1 or 2, and R1, R3, R4, R12 and R14 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  描述了公式（I）中的四氢-4H-吡啶并[1,2-a]嘧啶及其相关化合物作为HIV整合酶抑制剂和HIV复制抑制剂，其中n是等于零、1或2的整数，R1、R3、R4、R12和R14在此定义。这些化合物对于预防和治疗HIV感染以及预防、延缓发病和治疗艾滋病非常有用。这些化合物可作为化合物本身或药学上可接受的盐的形式用于对抗HIV感染和艾滋病。这些化合物及其盐可作为成分用于制药组合物中，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors
  申请人：——

  公开号：US20040019019A1

  公开（公告）日：2004-01-29

  The current invention discloses useful bicyclic and tricyclic amidino derivative compounds, pharmaceutical compositions containing these novel compounds, and to their use as nitric oxide synthase inhibitors.

  当前发明揭示了有用的双环和三环氨基甲酰衍生物化合物，含有这些新化合物的制药组合物，并且它们作为一氧化氮合酶抑制剂的用途。